medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2009, Number 3

<< Back

Rev Invest Clin 2009; 61 (3)

Guidelines in RA treatment: concepts on safety and recomendations using anti-TNF-α inhibitors

Diaz-Jouanen E, Abud-Mendoza C. Garza- Elizondo MA, Medrano- Ram¨ªrez G, Burgos- Vargas R, Orozco- Alcal¨¢ JJ, Pacheco-Tena CF , Pineda C , Pozos-Esp¨ªndola JC, Ramos-Niembro F, Robles-San-Rom¨¢n M, Santana-Sahag¨²n JE

Language: Spanish
References: 100
Page: 252-266
PDF size: 115.97 Kb.


ABSTRACT

Recommendations for the use of Disease-Modifying Antirheumatic Drugs (DMARD) with both conventional and biological agents in Rheumatoid Arthritis (RA) must be based on their safety profile, adverse effects, risks, and advantages. With the purpose of presenting the most updated information about the safety of tumor necrosis factor alpha (TNFα) antagonists, in this article we summarize the literature published during the last three years about this sort of biological agents in specific clinical situations, such as risk of developing infections, cancer, cardiovascular diseases, and autoimmunity; as well as their administration to patients who will undergo surgical procedures, pregnant and/or breast-feeding women, and patients who need immunizations. Likewise, in this analysis we offer specific recommendations, based on evidence, for the best anti-TNF-alfa management.


REFERENCES

  1. Díaz-Jouanen E, Abud-Mendoza C, Garza-Elizondo MA, Medrano- Ramírez G, Orozco Alcalá JJ, Pacheco-Tena CF y cols. Recomendaciones para el tratamiento médico de la artritis reumatoide. Rev Invtest Clin 2005; 57: 735-55.

  2. Dixon WG, Watson K, Lunt M, Hyrich KL. British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, and Symmons, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy. Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.

  3. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti–tumor necrosis factor-therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-64.

  4. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor-antagonists. Arthritis Rheum 2007; 56: 1125-33.

  5. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova- Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 2368-76.

  6. Costenbader KH, Glass R, Cui J, Shadick N. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis JAMA 2006; 296: 2201. (letter).

  7. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007; 46: 1157-60.

  8. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalization with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66: 1339-44.

  9. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.

  10. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova- Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12.

  11. Askling J, Dixon W. The safety of anti-tumor necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 138-44.

  12. Nasir A, Greenberg JD, TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries. Bull NYU Hosp Jt Dis 2006; 65: 178-81.

  13. Beglingera C, Dudlerb J, Mottetc C, Nicodd L, Seibolde F, Villiger PM, et al. Screening for tuberculosis infection before initiation of anti-TNF-a therapy. Swiss Med Wkly 2007; 137: 621-22.

  14. Available in: http://www.fda.gov/cder/drug/InfoSheets/HCP/ TNF_blockersHCP.html

  15. Maillefert JF, Muller G, Falgarone G, Bour JB, Ratovohery D, Dougados M et al. Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61: 635-7.

  16. Ghavami S, Hashemi M, Kadkhoda K, Alavian SM, Bay GH, Los M. Apoptosis in liver diseases-detection and therapeutic applications. Med Sci Monit 2005; 11: RA337-RA345.

  17. Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, and Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007; 34: 1353-5.

  18. Nathan DM, Angus PW and Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor a therapy: Guidelines for clinical approach. J Gastroenterol Hepatolol 2006; 21: 1366-71.

  19. Galeazzi M, Giannitti C, Manganelli S, Benucci M, Scarpato S, Bazzani C, Caporali R, Sebastiani GD. Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev 2008 Aug 8[Epub ahead of print].

  20. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH [Rheumatoid arthritis and risk of cancer]. Ugeskr Laeger 1998; 160: 3069-73.

  21. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978; 31: 691-6.

  22. Katusic S, Beard CM, Kurland LT, Weiss JW, Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 1985; 78(1A): 50-5.

  23. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998; 317: 180-1.

  24. Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther 2001; 15: 1101-8.

  25. Kwon JH, Farrell RJ. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol 2005; 56: 169-78.

  26. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and antitumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-51.

  27. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-8.

  28. Baecklund E, Askling J, Rosenquist R, Ekborm A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004; 16: 254-61.

  29. Geborek P, Bladstrom A, Turesson C, Gulfe A, Peterson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703.

  30. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34: 819-36.

  31. Wolfe F, Michaud K. The effect of methotrexate and anti-tumour necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433-9.

  32. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30: 36-40.

  33. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-a, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 2005; 4: 153-61.

  34. Del Rincón I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45.

  35. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? [Review]. Arthritis Rheum 2002; 46: 862-73.

  36. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005; 52: 412-20.

  37. Watson DJ, Rhodes T, Guess HA. All- cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30: 1196–202.

  38. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236–41.

  39. Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology (Oxford) 2005; 44: 1473-82.

  40. Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, et al. Does tumor necrosis factor a inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008; 58: 667-77.

  41. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).Circulation 2004; 109: 1594-602.

  42. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-40.

  43. Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 2004; 31: 867-74.

  44. Warner TD, Mitchell JA, COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal antiinflammatory drugs. Lancet 2008; 371: 270-3.

  45. Giles JT, Barthon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004; 19: 320-34.

  46. Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 1072-82.

  47. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Ann Rheum Dis 2001; 60: 214-7.

  48. Hamalainen M, Raunio P, von Essen R. Postoperative wound infection in rheumatoid arthritis surgery. Clin Rheumatol 1984; 3: 329-35.

  49. Bongartz T, Halligan CS, Osmon DR, Hanssen AD, Bamlet WR, Matteson EL. Incidence and risk factors for prosthetic joint infections in patients with rheumatoid arthritis following total knee and total hip replacement Arthritis Rheum 2005; 52:(Suppl. 9): 1449. [abstract].

  50. den Broeder A, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007; 34: 689-95.

  51. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopedic foot and ankle surgery during tumor necrosis-alpha inhibition therapy. Foot Ankle Int 2004; 25: 331-5.

  52. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006; 55: 333-7.

  53. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Register. Arthritis Rheum 2006; 54: 2368-76.

  54. Pieringer H, Stuby U, Biesenbach G. Patients with rheumatoid arthritis undergoing surgery: how should we deal with antir heumatic treatment? Semin Arthritis Rheum 2007; 36: 278-86.

  55. Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 2007; 25: 430-6.

  56. Pham T, Claudepierre P, Deprez X, Fautrel B, Goupille P, Hilliquin P, et al. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR). Joint Bone Spine 2005; 72(Suppl. 1): S49-S50.

  57. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344; 1105-10.

  58. Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor a:? findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-90.

  59. Ramos NF. Autoinmunidad, enfermedades autoinmunes y otros procesos mediados inmunológicamente, asociados con el empleo de los inhibidores del factor de necrosis tumoral alfa. En: Terapia biológica en las enfermedades reumáticas. Ramos NF, Orozco AJ (eds.). México: Elsevier-Masson-Doyma, S.A.: 2006, p. 307-43.

  60. Ramos-Casals M, Brito-Zeron P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNFtargeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86: 242-51.

  61. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52: 2447-51.

  62. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004; 111: 352-6.

  63. Murphy CC, Greiner K, Plskova J, Duncan L, Frost A, Isaacs JD, et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 2004; 122: 845-51.

  64. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003; 110: 1449-53.

  65. Lanthier N, Parc C, Scavennec R, Dhôte R, Brézin AP, Guillevin L. Infliximab in the treatment of posterior uveitis in Behçet’s disease. Long term follow up in four patients. Presse Med 2005; 34: 916-8.

  66. Lim LL, Fraundfelder FW, Rosembaum JT. Do tumor necrosis factor inhibitors cause uveitis? Arthritis Rheum 2007; 56: 3248-52.

  67. Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62: 829-34.

  68. Verea MM, del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004; 38: 54-7.

  69. Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004; 3: 439-40.

  70. Sfikakis PP, Lliopoulus A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy. Arthritis Rheum 2005; 52: 2513-8.

  71. Dutz JP. Tumor necrosis factor-an inhibition and palmoplantar pustulosis: Janus- faced therapy? J Rheumatol 2007; 34: 247-9.

  72. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF{alpha} therapy. Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2008 Apr 2. [Epub ahead of print].

  73. Physician’s Drug Handbook. 5th. Ed. Springhouse, Pennsylvania: Springhouse Corp.; 1993, p. vii.

  74. Ramos NF. Fármacos modificadores de la enfermedad. En: Reumatología: Diagnóstico y Tratamiento. Ramos NF, Lom OH (eds.). México, D.F.: El Manual Moderno; 2008, p. 503-21.

  75. Hunt JS, Chen HL, Miller L. Tumor necrosis factors: pivotal components of pregnancy? Biol Reprod 1996; 54: 554-62.

  76. Sills ES, Perlor M, Tucker MJ, Kaplan CR, Palermo GD. Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anticytokine treatment for rheumatoid arthritis. Am J Rreprod Immunol 2001; 46: 366-8.

  77. Skomsvoll JF, Wallenius M, Koksvik HS, Rodevand E, Salvesen KA, Spigset O, et al. Drug insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol 2007; 3: 156-64.

  78. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46: 695-8.

  79. Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 2006; 33: 1014-7.

  80. Carter JD, Ladhani A, Rica L, Valeriano J, Vasey FB. A safety assessment of TNF antagonist during pregnancy: a review of the FDA database. Arthritis Rheum 2007; 56 (Suppl. 9); S286. (Abstract).

  81. Ostensen M, Eigenmann GO. Etanercept in breast milk. J Rheumatol 2004; 31:1017-8.

  82. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4: 1255-8.

  83. Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 2006; 54: 2701-2.

  84. Joven BE, García-González AJ, Ruiz T, Moreno E, Cebrian L, Valero M, et al. Pregnancy in women receiving anti TNF therapy. Experience in Spain. Arthritis Rheum 2005; 52(Suppl. 9): S349. (Abstract).

  85. García J, Joven B, Ruiz T, Moreno E, Cebrian L, Valero M, et al. Pregnancy in women receiving anti TNF alpha therapy. Experience in Spain. Annals Rheum Dis 2006; 65(Suppl. II): S317. (Abstract).

  86. Strangfeld A, Listing J, Rau R, Schneider M, Hierse F, Krause A, et al. Pregnancy outcome after exposure to biologics: Results from the German Bio logics Register RABBIT. Arthritis Rheum 2007; 56(Suppl. 9): S311. (Abstract).

  87. Chambers CD, Johnson DL, Jones KL. Pregnancy outcome in women who were exposed to anti-TNF alpha medications: The OTIS rheumatoid arthritis in Pregnancy Study. Arthritis Rheum 2004: 50(Suppl. 9); S479. (Abstract).

  88. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.

  89. Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O’Fallon WM, et al. Survival in rheumatoid arthritis: a population- based analysis of trends over 40 years. Arthritis Rheum 2003; 48: 54-8.

  90. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-300.

  91. Glück T. Vaccinate your immunocompromised patients! Rheumatology (Oxford) 2006; 45: 9-10.

  92. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, October 2007- September 2008. Ann Intern Med 2007; 147: 725-9.

  93. Kroger A, Atkinson W, Marcuse E, Pickering L General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP) CDC 2006/55(RR15); 1-48.

  94. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, et al. American College of Rheumatology 2008 recommendations for the use of non-biologic and biologic disease- modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (Arthritis Care&Research) 2008; 59: 762-84.

  95. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 106-11.

  96. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007; 46: 608-11.

  97. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 272-9.

  98. Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007; 34: 952-7.

  99. Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67: 713-6.

  100. 100.Gelinck LB, van der Bijl AE, Visser LG, Huizinga TW, van Hogezand RA, Rijkers GT, et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine Vaccine 2008; 26: 3528-33.




2020     |     www.medigraphic.com